CV Therapeutics

Developer of two FDA-approved therapeutics for cardiovascular indications

CV Therapeutics was focused on the discovery, development, and commercialization of small molecule therapeutics to treat chronic cardiovascular diseases. The company gained FDA approval for two products, Ranexa (ranolazine) for angina and Lexiscan (regadenoson) for myocardial perfusion imaging. CV Therapeutics completed its IPO on NASDAQ in 1996 and was acquired by Gilead in 2009.

Status

IPO in 1996; Acquired by Gilead Sciences in 2009

Year of Investment

1991

Strategy

Life Sciences

Subsector

Development-Stage Therapeutics

Location

Bay Area, California

Frazier Team